Featured Publications
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated risk
2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.Peer-Reviewed Original ResearchConceptsSocioecological modelGermline testingHealthcare institutionsCancer genetic testingHereditary cancer implicationsEquity frameworkBlack malesCancer screeningReduce disparitiesBackgroundBlack menCommunity liaisonCommunity stakeholdersMixed-methods approachOvercome barriersImprovement PartnershipCommunity eventsCascade testingModified Delphi modelRate of prostate cancerGenetic testingCancer implicationsEducation programsBlack menEquitable strategiesIncreased engagementBRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients
Cheng H, Shevach J, Castro E, Couch F, Domchek S, Eeles R, Giri V, Hall M, King M, Lin D, Loeb S, Morgan T, Offit K, Pritchard C, Schaeffer E, Szymaniak B, Vassy J, Katona B, Maxwell K. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology 2024, 10: 1272-1281. PMID: 39052257, DOI: 10.1001/jamaoncol.2024.2185.Peer-Reviewed Original ResearchBRCA1/2 PVCancer riskPoly ADP-ribose polymeraseGenetic testingCancer genetic testingFamilial cancer riskPrimary care cliniciansEvidence of increased riskBRCA1/2-PV carriersMale carriersIncreased genetic testingRisk of breastRisk reductionCancer early detectionCancer-predisposing variantsClinical trial opportunitiesCancer therapy optionsCare cliniciansTargeted risk managementCancer screeningPV carriersHereditary cancerADP-ribose polymeraseGuideline recommendationsEarly cancer detectionHealth care utilization and behavior changes after workplace genetic testing at a large US health care system
Charnysh E, Pal S, Reader J, Uhlmann W, McCain S, Sanghavi K, Blasco D, Brandt R, Feero W, Ferber R, Giri V, Hendy K, Prince A, Lee C, Roberts J, consortium I, Crumpler N, Leader A, Mathews D, Ryan K, Spector-Bagdady K, Vogle A, Brothers K, Clayton E, Deverka P, Ellis T, Goldenberg A, Mockus S, Morton C, Rueter J, Witham B, Bessey E, Gordon E, Lee L, Roberts J, Saidi F. Health care utilization and behavior changes after workplace genetic testing at a large US health care system. Genetics In Medicine 2024, 26: 101160. PMID: 38733246, PMCID: PMC11566502, DOI: 10.1016/j.gim.2024.101160.Peer-Reviewed Original ResearchHealth behavior changeU.S. healthcare systemHealthcare utilizationIncreased riskAssociated with health behavior changesBehavioral changesHealthcare systemPromote health behavior changeGenetic testingImprove employee healthHeart diseaseSelf-reported dataLogistic regression analysisElectronic surveyMedication changesDescriptive statisticsHealthcarePGx resultsEmployee healthHealth implicationsRegression analysisHealthPGxWorkplaceCancerPD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY
Loeb S, Gross L, Cheng H, Rivera A, Keith S, Byrne N, Nolasco T, Giri V. PD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY. Journal Of Urology 2024, 211: e62. DOI: 10.1097/01.ju.0001009540.33579.43.01.Peer-Reviewed Original ResearchToward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R, Wyatt A. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precision Oncology 2024, 8: e2300654. PMID: 38547422, PMCID: PMC10994438, DOI: 10.1200/po.23.00654.Peer-Reviewed Original ResearchConceptsClinical genomic testingGenomic testingProstate cancerTumor tissuesPoly (ADP-ribose) polymerase inhibitorsPlasma cell-free DNAHereditary cancer implicationsLow tumor fractionAdvanced prostate cancerDNA damage repair genesHealth care professionalsCell-free DNANonpathogenic variantsPatient's germlineOptimal patient careSomatic alterationsSubclonal alterationsClinical decision makingClonal hematopoiesisCare professionalsGenotyping testPoor prognosisTumor fractionPatient careCancer managementTARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testingAddressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board
Loeb S, Cheng H, Paller C, Weg E, Johnson J, Gross L, Keith S, Russo J, Hathaway F, Rivera A, Giri V. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer And Prostatic Diseases 2024, 1-3. PMID: 38172199, DOI: 10.1038/s41391-023-00778-9.Peer-Reviewed Original ResearchP864: Employees’ views and healthcare utilization following employer-sponsored pharmacogenomic testing at a large US healthcare system
Charnysh E, Pal S, Reader J, McCain S, Hendy K, Sanghavi K, Uhlmann W, Feero W, Prince A, Brandt R, Ferber R, Giri V, Lee C, Roberts J. P864: Employees’ views and healthcare utilization following employer-sponsored pharmacogenomic testing at a large US healthcare system. Genetics In Medicine Open 2024, 2: 101778. DOI: 10.1016/j.gimo.2024.101778.Peer-Reviewed Original Research
2023
Liver Transplantation in a Woman with Mahvash Disease
Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri V, Miller J, Maley W, Shah A, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler D. Liver Transplantation in a Woman with Mahvash Disease. New England Journal Of Medicine 2023, 389: 1972-1978. PMID: 37991855, DOI: 10.1056/nejmoa2303226.Peer-Reviewed Original ResearchConceptsPortal hypertensionLiver transplantationPancreatic hypertrophyMahvash diseasePancreatic α cell hyperplasiaAbsence of cirrhosisNoncirrhotic portal hypertensionΑ-cell hyperplasiaRare genetic disorderSerum glucagonDefinitive treatmentGlucagon levelsVascular diseaseMedical CenterHypertensionDiseaseAmmonia levelsHyperglucagonemiaGenetic disordersTransplantationHypertrophyGlucagonWomenHematemesisCirrhosisGenomic testing in voluntary workplace wellness programs in the US: Evidence and challenges
Cohn B, Ryan K, Hendy K, Callahan K, Roberts J, Spector‐Bagdady K, Mathews D, Blasco D, Crumpler N, Feero W, Ferber R, Giri V, Prince A, Sanghavi K, Uhlmann W, Vogle A, Lee C. Genomic testing in voluntary workplace wellness programs in the US: Evidence and challenges. Molecular Genetics & Genomic Medicine 2023, 11: e2245. PMID: 37592452, PMCID: PMC10655502, DOI: 10.1002/mgg3.2245.Peer-Reviewed Original ResearchTechnology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Giri V, Keith S, Cheng H, Leader A, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Loeb S. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 10598-10598. DOI: 10.1200/jco.2023.41.16_suppl.10598.Peer-Reviewed Original ResearchDecisional conflictGenetic testingPre-test genetic counselingGermline testingGenetic counselingProstate cancerRandomized non-inferiority trialHereditary cancer risk assessmentGermline genetic testingClinical trial eligibilityNon-inferiority trialProstate Cancer FoundationProstate cancer managementCancer genetic testingDecision Conflict ScaleCancer risk assessmentGermline evaluationTrial eligibilityPrimary endpointMean ageStudy protocolCancer managementGenetics educationAnalysis of covarianceCancer FoundationA generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
Ritch E, Herberts C, Warner E, Ng S, Kwan E, Bacon J, Bernales C, Schönlau E, Fonseca N, Giri V, Maurice-Dror C, Vandekerkhove G, Jones S, Chi K, Wyatt A. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. Npj Precision Oncology 2023, 7: 27. PMID: 36914848, PMCID: PMC10011564, DOI: 10.1038/s41698-023-00366-z.Peer-Reviewed Original ResearchMetastatic prostate cancerDDR gene alterationsProstate cancerGene alterationsDDR deficiencyOngoing clinical trialsPlasma cell-free DNADNA damage repair defectsLiquid biopsy specimensMismatch repair deficiencyLeukocyte DNA samplesBladder cancer samplesCell-free DNABiopsy specimensBladder cancerClinical trialsTreatment benefitMetastatic prostateFactors related to men’s experience with prostate cancer germline testing.
Giri V, Gross L, Hartman R, Leader A, Whang Y, Couvillon A, Cheng H, Paller C, Loeb S, Karsh L, Friedman S, Beer T, Sokolova A, Keith S. Factors related to men’s experience with prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 128-128. DOI: 10.1200/jco.2023.41.6_suppl.128.Peer-Reviewed Original ResearchInherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).
Couvillon A, Turkbey B, Choyke P, Lee-Wisdom K, McKinney Y, Sidlow R, Mullane M, Giri V, Morgan T, Cheng H, Merino M, Figg W, Pinto P, Dahut W, Karzai F. Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). Journal Of Clinical Oncology 2023, 41: 390-390. DOI: 10.1200/jco.2023.41.6_suppl.390.Peer-Reviewed Original ResearchGermline pathogenic variantsProstate cancerActive surveillancePathogenic variantsMedian ageRadiation therapyMonitoring of PCaDiagnosis of PCaDistinct pathogenic variantsHigh-risk geneticsPIRADS 3 lesionsPIRADS 4 lesionsISUP grade group 1Grade group 1Localized prostate cancerMonoallelic pathogenic variantsDNA mismatch repair genesLikely pathogenic variantsProstate cancer diagnosisMismatch repair genesDefinitive treatmentPSA monitoringProstate biopsyBiopsy specimensRisk factorsUsefulness of podcasts to provide public education on prostate cancer genetics
Loeb S, Sanchez Nolasco T, Siu K, Byrne N, Giri V. Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate Cancer And Prostatic Diseases 2023, 26: 772-777. PMID: 36681741, DOI: 10.1038/s41391-023-00648-4.Peer-Reviewed Original Research
2022
ASCO Living Guidelines: The Next Frontier
Giri V, Oliver T, Rumble R, Friedberg J, Miller K, Geisel R. ASCO Living Guidelines: The Next Frontier. Journal Of Clinical Oncology 2022, 41: 955-957. PMID: 36534929, DOI: 10.1200/jco.22.02344.Peer-Reviewed Original ResearchAssessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021
Halloran M, Keiffer G, Giri V, Gross L, Wilde L, Palmisiano N, Porcu P, Kasner M. Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021. Blood 2022, 140: 11466-11467. DOI: 10.1182/blood-2022-165510.Peer-Reviewed Original ResearchReply to X. Luo et al
Giri V, Oliver T, Rumble R, Geisel R. Reply to X. Luo et al. Journal Of Clinical Oncology 2022, 41: 1150-1151. PMID: 36315930, DOI: 10.1200/jco.22.02126.Commentaries, Editorials and LettersAttitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4